| Methods |
Uncontrolled study |
| Participants |
4 women with ovarian cancer (disease status at study entry not described) |
| Interventions |
Monoclonal antibody (MJ01 ‐ CA‐125) |
| Outcomes |
Immune response: cellular |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
High risk |
Uncontrolled trial |
| Allocation concealment (selection bias) |
High risk |
Uncontrolled trial |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Selective reporting (reporting bias) |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Other bias |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
